Immunotherapy Drugs Market Growth & Trends
The global immunotherapy drugs market size is expected to reach over USD 200.55 billion by 2030, according to a new report by Grand View Research Inc. The industry is expected to grow at a CAGR of 6.92% from 2022 to 2030. The key factors contributing to the lucrative growth of the industry include increased awareness about chronic diseases including cancer, autoimmune diseases, inflammatory diseases, and infectious diseases coupled with supportive government policies for drug approval.The rising adoption of targeted therapies for chronic disease treatment is expected to increase inclination towards immunotherapy drugs, thereby driving the industry over the forecast period.
For instance, in May 2022, AstraZeneca and Daiichi Sankyo’s Enhertu (trastuzumab) received U.S. approval for treating HER2-positive breast cancer. Other targeted immunotherapy drugs include Kadcyla (trastuzumab emtansine) and Tecentriq (atezolizumab). In June 2022, F. Hoffmann-La Roche Ltd. received EU approval for Tecentriq as an adjuvant treatment for NSCLC. In addition, growing healthcare infrastructure in low- and middle-income countries coupled with increased research & development by key players is anticipated to contribute to the industry growth. For instance, in December 2021, Novartis AG collaborated with BeiGene, Ltd. for ociperlimab (BGB-A1217), therefore expanding its R&D activities in immune-oncology.
In August 2021, Pfizer, Inc. shared positive results from phase 2b/3 clinical trial of ritlecitinib for treating alopecia areata. Moreover, the rise in the incidence of cancer cases worldwide is expected to drive the demand for immunotherapy drugs. As per Globocan reports, an estimated 19.3 million new oncology cases were diagnosed in 2020. Moreover, according to the European Society of Medical Oncology, cancer incidence in Europe is anticipated to rise by 21% between 2020 and 2040. Thus, approvals of various immunotherapy drugs for cancer treatment are predicted to increase industry growth.
Immunotherapy Drugs Market Report Highlights
- The monoclonal antibodies drug type segment accounted for the largest revenue share in 2021
- The growth can be attributed to the high demand for biologics treatment for various chronic diseases, such as cardiovascular, respiratory, and autoimmune diseases
- The cancer segment dominated the marketplace in 2021 due to the increased incidence of cancer globally and improved healthcare infrastructure in low- and middle-income countries
- North America dominated the industry in 2021 accounting for the maximum revenue share
- This is due to the increased adoption of immunotherapy, supportive reimbursement policies, and increased healthcare expenditure in the region
- Chapter 1 Methodology and Scope
- 1.1 Market segmentation
- 1.1.1 Estimates and forecast timeline
- 1.2 Research Methodology
- 1.3 Information Procurement
- 1.3.1 Purchased database
- 1.3.2 GVR’S internal database
- 1.3.3 Secondary sources
- 1.3.4 Primary research
- 1.3.5 Details of primary research
- 1.3.6 List of primary sources
- 1.4 Information or data analysis
- 1.4.1 Data analysis models
- 1.5 Market Formulation & Validation
- 1.6 Model Details
- 1.6.1 Commodity flow analysis
- 1.6.1.1 Approach 1: Commodity Flow Approach
- 1.6.1.2 Approach 2: Country-wise market estimation using bottom-up approach
- 1.7 Global Market: CAGR Calculation
- 1.8 Research Assumptions
- 1.9 List of Secondary Sources
- 1.10 List of Abbreviations
- 1.11 Objectives
- 1.11.1 Objective 1
- 1.11.2 Objective 2
- 1.11.3 Objective 3
- 1.11.4 Objective 4
- Chapter 2 Executive Summary
- 2.1 Market Summary
- Chapter 3 Market Variables, Trends & Scope
- 3.1 Market Lineage Outlook
- 3.1.1 Parent market outlook
- 3.2 Regulatory framework
- 3.3 Penetration and Growth Prospect Mapping
- 3.4 Pipeline Analysis
- 3.5 Market Dynamics
- 3.5.1 Market driver analysis
- 3.5.2 Market restraint analysis
- 3.6 PESTEL Analysis
- Chapter 4 Global Immunotherapy Drugs Market - Segment Analysis, By Drug Type, 2018 - 2030 (USD Billion)
- 4.1 Global Immunotherapy Drugs Market: Drug Type Movement Analysis
- 4.2 Monoclonal Antibodies
- 4.2.1 Monoclonal antibodies market estimates and forecast, 2018 - 2030 (USD Billion)
- 4.3 Immunomodulators
- 4.3.1 Immunomodulators market estimates and forecast, 2018 - 2030 (USD Billion)
- 4.4 Vaccine
- 4.4.1 Vaccine market estimates and forecast, 2018 - 2030 (USD Billion)
- Chapter 5 Global Immunotherapy Drugs Market - Segment Analysis, By Indication, 2018 - 2030 (USD Billion)
- 5.1 Global Immunotherapy Drugs Market: Indication Movement Analysis
- 5.2 Cancer
- 5.2.1 Cancer market estimates and forecast, 2018 - 2030 (USD Billion)
- 5.3 Autoimmune Diseases
- 5.3.1 Autoimmune diseases market estimates and forecast, 2018 - 2030 (USD Billion)
- 5.4 Infectious Diseases
- 5.4.1 Infectious diseases market estimates and forecast, 2018 - 2030 (USD Billion)
- 5.5 Others
- 5.5.1 Others market estimates and forecast, 2018 - 2030 (USD Billion)
- Chapter 6 Immunotherapy Drugs Market: Segment Analysis, by Region, 2018 - 2030 (USD Billion)
- 6.1 Immunotherapy Drugs Market: Regional Movement Analysis
- 6.1.1 North America
- 6.1.1.1 North America market estimates and forecast, 2018 - 2030 (USD Billion)
- 6.1.1.2 U.S.
- 6.1.1.2.1 U.S. market estimates and forecast, 2018 - 2030 (USD Billion)
- 6.1.1.3 Canada
- 6.1.1.3.1 Canada market estimates and forecast, 2018 - 2030 (USD Billion)
- 6.1.2 Europe
- 6.1.2.1 Europe market estimates and forecast, 2018 - 2030 (USD Billion)
- 6.1.2.2 U.K.
- 6.1.2.2.1 U.K. market estimates and forecast, 2018 - 2030 (USD Billion)
- 6.1.2.3 Germany
- 6.1.2.3.1 Germany market estimates and forecast, 2018 - 2030 (USD Billion)
- 6.1.2.4 France
- 6.1.2.4.1 France market estimates and forecast, 2018 - 2030 (USD Billion)
- 6.1.2.5 Spain
- 6.1.2.5.1 Spain market estimates and forecast, 2018 - 2030 (USD Billion)
- 6.1.2.6 Italy
- 6.1.2.6.1 Italy market estimates and forecast, 2018 - 2030 (USD Billion)
- 6.1.2.7 Russia
- 6.1.2.9.1 Russia market estimates and forecast, 2018 - 2030 (USD Billion)
- 6.1.3 Asia Pacific
- 6.1.3.1 Asia Pacific market estimates and forecast, 2018 - 2030 (USD Billion)
- 6.1.3.2 Japan
- 6.1.3.2.1 Japan market estimates and forecast, 2018 - 2030 (USD Billion)
- 6.1.3.3 China
- 6.1.3.3.1 China market estimates and forecast, 2018 - 2030 (USD Billion)
- 6.1.3.4 India
- 6.1.3.4.1 India market estimates and forecast, 2018 - 2030 (USD Billion)
- 6.1.3.5 Australia
- 6.1.3.5.1 Australia market estimates and forecast, 2018 - 2030 (USD Billion)
- 6.1.3.5 South Korea
- 6.1.3.5.1 South Korea market estimates and forecast, 2018 - 2030 (USD Billion)
- 6.1.3.6 Singapore
- 6.1.3.6.1 Singapore market estimates and forecast, 2018 - 2030 (USD Billion)
- 6.1.4 Latin America
- 6.1.4.1 Latin America market estimates and forecast, 2018 - 2030 (USD Billion)
- 6.1.4.2 Brazil
- 6.1.4.2.1 Brazil market estimates and forecast, 2018 - 2030 (USD Billion)
- 6.1.4.3 Mexico
- 6.1.4.3.1 Mexico market estimates and forecast, 2018 - 2030 (USD Billion)
- 6.1.4.4 Argentina
- 6.1.4.4.1 Argentina market estimates and forecast, 2018 - 2030 (USD Billion)
- 6.1.5 Middle East & Africa
- 6.1.5.1 Middle East & Africa market estimates and forecast, 2018 - 2030 (USD Billion)
- 6.1.5.2 South Africa
- 6.1.5.2.1 South Africa market estimates and forecast, 2018 - 2030 (USD Billion)
- 6.1.5.3 Saudi Arabia
- 6.1.5.3.1 Saudi Arabia market estimates and forecast, 2018 - 2030 (USD Billion)
- 6.1.5.5 United Arab Emirates
- 6.1.5.5.1 United Arab Emirates market estimates and forecast, 2018 - 2030 (USD Billion)
- Chapter 7 Global Immunotherapy Drugs Market: Competitive Analysis
- 7.1 Recent Developments and Impact Analysis, by Key Market Participants
- 7.1.1 Major deals & strategic alliances analysis
- 7.1.1.1 New Product Launches
- 7.1.1.2 Mergers and Acquisitions
- 7.1.1.3 Partnerships & Agreements
- 7.2 Company Categorization
- 7.2.1 Innovators
- 7.2.2 Market Leaders
- 7.2.3 Emerging Players
- 7.2.4 Heat Map Analysis
- 7.3 Company Market Position Analysis
- 7.4 Vendor Landscape
- 7.4.1 List of Key Distributors and Channel Partners
- 7.4.2 List of Potential End Users
- 7.4.3 Key Company Market Share Analysis, 2021
- 7.5 Company Market Share, 2021
- 7.5.1 Competitive Dashboard Analysis
- 7.6 Private Companies
- 7.6.1 List of Key Emerging Companies
- 7.6.2 Regional Network Map
- 7.7 Company Profiles
- 7.7.1 Amgen, Inc.
- 7.7.1.1 Company overview
- 7.7.1.2 Financial performance
- 7.7.1.3 Product benchmarking
- 7.7.1.4 Strategic initiatives
- 7.7.2 Novartis AG
- 7.7.2.1 Company overview
- 7.7.2.2 Financial performance
- 7.7.2.3 Product benchmarking
- 7.7.2.4 Strategic initiatives
- 7.7.3 AbbVie, Inc.
- 7.7.3.1 Company overview
- 7.7.3.2 Financial performance
- 7.7.3.3 Product benchmarking
- 7.7.3.4 Strategic initiatives
- 7.7.4 Pfizer, Inc.
- 7.7.4.1 Company overview
- 7.7.4.2 Financial performance
- 7.7.4.3 Product benchmarking
- 7.7.4.4 Strategic initiatives
- 7.7.5 F. Hoffmann-La Roche Ltd.
- 7.7.5.1 Company overview
- 7.7.5.2 Financial performance
- 7.7.5.3 Product benchmarking
- 7.7.5.4 Strategic initiatives
- 7.7.6 Johnson & Johnson Services, Inc.
- 7.7.6.1 Company overview
- 7.7.6.2 Product benchmarking
- 7.7.6.3 Strategic initiatives
- 7.7.7 AstraZeneca
- 7.7.7.1 Company overview
- 7.7.7.2 Financial performance
- 7.7.7.3 Product benchmarking
- 7.7.8 GSK
- 7.7.7.1 Company overview
- 7.7.7.2 Financial performance
- 7.7.7.3 Product benchmarking
- 7.7.7.4 Strategic initiatives
- 7.7.9 Sanofi
- 7.7.9.1 Company overview
- 7.7.9.2 Financial performance
- 7.7.9.3 Product benchmarking
- 7.7.9.4 Strategic initiatives
- 7.7.10 Bayer AG
- 7.7.7.1 Company overview
- 7.7.7.2 Financial performance
- 7.7.7.3 Product benchmarking
- 7.7.7.4 Strategic initiatives
Research Assistance
Learn how to effectively navigate the market research process to help guide your organization on the journey to success.
Download eBook